|
Overview of the Management of Higher-Risk Myelodysplastic Syndromes |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms |
Jul 2019 |
Surgical Pathology Clinic |
Myelodysplastic Syndromes (MDS) |
|
Paroxysmal Nocturnal Hemoglobinuria |
Jan 2024 |
StatPearls |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia |
Jan 2021 |
Seminars in Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Genomics of myelodysplastic/myeloproliferative neoplasm |
May 2023 |
Seminars in Diagnostic Pathology |
Myelodysplastic Syndromes (MDS) |
|
Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates |
Jan 2019 |
Semin Hematol |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study |
Jun 2020 |
Scientific Reports |
Myelodysplastic Syndromes (MDS) |
|
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
Jun 2023 |
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
